Lambros T Koufariotis
Overview
Explore the profile of Lambros T Koufariotis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
598
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Newell F, Pires da Silva I, Johansson P, Menzies A, Wilmott J, Addala V, et al.
Cancer Cell
. 2025 Feb;
43(3):563.
PMID: 39919735
No abstract available.
2.
Liu L, Zhang J, Wood S, Newell F, Leonard C, Koufariotis L, et al.
BMC Genomics
. 2024 Sep;
25(1):898.
PMID: 39350042
Background: Lung cancer is a heterogeneous disease and the primary cause of cancer-related mortality worldwide. Somatic mutations, including large structural variants, are important biomarkers in lung cancer for selecting targeted...
3.
Brosda S, Aoude L, Bonazzi V, Patel K, Lonie J, Belle C, et al.
Genome Med
. 2024 Jul;
16(1):90.
PMID: 39020404
Background: Oesophageal adenocarcinoma (OAC) is a highly heterogeneous cancer with poor survival. Standard curative treatment is chemotherapy with or without radiotherapy followed by oesophagectomy. Genomic heterogeneity is a feature of...
4.
Fielding D, Lakis V, Dalley A, Chittoory H, Newell F, Koufariotis L, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398180
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is often the only source of tumor tissue from patients with advanced, inoperable lung cancer. EBUS-TBNA aspirates are used for the diagnosis, staging, and...
5.
Lonie J, Brosda S, Bonazzi V, Aoude L, Patel K, Brown I, et al.
Front Immunol
. 2023 Nov;
14:1220129.
PMID: 37965317
A plateau in treatment effect can be seen for the current 'one-size-fits-all' approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment...
6.
Davidson A, Dressel U, Norris S, Canson D, Glubb D, Fortuno C, et al.
Genome Med
. 2023 Sep;
15(1):74.
PMID: 37723522
Background: Many families and individuals do not meet criteria for a known hereditary cancer syndrome but display unusual clusters of cancers. These families may carry pathogenic variants in cancer predisposition...
7.
Tran K, Addala V, Johnston R, Lovell D, Bradley A, Koufariotis L, et al.
Nat Commun
. 2023 Sep;
14(1):5758.
PMID: 37717006
Cells within the tumour microenvironment (TME) can impact tumour development and influence treatment response. Computational approaches have been developed to deconvolve the TME from bulk RNA-seq. Using scRNA-seq profiling from...
8.
Aoude L, Brosda S, Ng J, Lonie J, Belle C, Patel K, et al.
J Mol Diagn
. 2023 Aug;
25(10):771-781.
PMID: 37544359
For patients with BRAF wild-type stage III and IV melanoma, there is an urgent clinical need to identify prognostic biomarkers and biomarkers predictive of treatment response. Circulating tumor DNA (ctDNA)...
9.
Naeini M, Newell F, Aoude L, Bonazzi V, Patel K, Lampe G, et al.
Nat Commun
. 2023 May;
14(1):3155.
PMID: 37258531
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients...
10.
Generalising uncertainty improves accuracy and safety of deep learning analytics applied to oncology
MacDonald S, Foley H, Yap M, Johnston R, Steven K, Koufariotis L, et al.
Sci Rep
. 2023 May;
13(1):7395.
PMID: 37149669
Uncertainty estimation is crucial for understanding the reliability of deep learning (DL) predictions, and critical for deploying DL in the clinic. Differences between training and production datasets can lead to...